{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T03:41:34Z","timestamp":1790048494806,"version":"4.0.1"},"reference-count":32,"publisher":"National Academy of Sciences","issue":"36","license":[{"start":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T00:00:00Z","timestamp":1597881600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.pnas.org"],"crossmark-restriction":true},"short-container-title":["Proc. Natl. Acad. Sci. U.S.A."],"published-print":{"date-parts":[[2020,9,8]]},"abstract":"<jats:title>Significance<\/jats:title>\n                  <jats:p>\n                    This paper characterizes a\n                    <jats:sc>d<\/jats:sc>\n                    -peptide HIV entry inhibitor, CPT31, in rhesus macaques. This nonhuman primate animal model provides the most robust evaluation of an in vivo antiviral prior to human trials. As described here, CPT31 is a promising HIV drug candidate because of its high potency and breadth, long half-life, and strong activity in this macaque model (both as a preventative and therapeutic agent). The efficacy data described here complete CPT31\u2019s preclinical studies, with clinical trials scheduled to start this year. These data also help establish\n                    <jats:sc>d<\/jats:sc>\n                    -peptides as an emerging class of therapeutics.\n                  <\/jats:p>","DOI":"10.1073\/pnas.2009700117","type":"journal-article","created":{"date-parts":[[2020,8,20]],"date-time":"2020-08-20T19:45:23Z","timestamp":1597952723000},"page":"22436-22442","update-policy":"https:\/\/doi.org\/10.1073\/pnas.cm10313","source":"Crossref","is-referenced-by-count":28,"title":["Prevention and treatment of SHIVAD8 infection in rhesus macaques by a potent\n                    <scp>d<\/scp>\n                    -peptide HIV entry inhibitor"],"prefix":"10.1073","volume":"117","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1347-2368","authenticated-orcid":false,"given":"Yoshiaki","family":"Nishimura","sequence":"first","affiliation":[{"name":"Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6496-2546","authenticated-orcid":false,"given":"J. Nicholas","family":"Francis","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112;"},{"name":"Navigen, Inc., Salt Lake City, UT 84108;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olivia K.","family":"Donau","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Jesteadt","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Reza","family":"Sadjadpour","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7348-1499","authenticated-orcid":false,"given":"Amanda R.","family":"Smith","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael S.","family":"Seaman","sequence":"additional","affiliation":[{"name":"Center for Virology and Vaccine Research, Beth Israel Deaconess Medical Center, Boston, MA 02215"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brett D.","family":"Welch","sequence":"additional","affiliation":[{"name":"Navigen, Inc., Salt Lake City, UT 84108;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Malcolm A.","family":"Martin","sequence":"additional","affiliation":[{"name":"Laboratory of Molecular Microbiology, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, MD 20892;"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3186-9684","authenticated-orcid":false,"given":"Michael S.","family":"Kay","sequence":"additional","affiliation":[{"name":"Department of Biochemistry, University of Utah School of Medicine, Salt Lake City, UT 84112;"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"341","published-online":{"date-parts":[[2020,8,20]]},"reference":[{"key":"e_1_3_4_1_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(02)09411-4"},{"key":"e_1_3_4_2_2","doi-asserted-by":"publisher","DOI":"10.1097\/00002030-200205030-00012"},{"key":"e_1_3_4_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM199803263381301"},{"key":"e_1_3_4_4_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1600693"},{"key":"e_1_3_4_5_2","first-page":"156","article-title":"Update of the drug resistance mutations in HIV-1: December 2010","volume":"18","author":"Johnson V. A.","year":"2010","unstructured":"V. A. Johnson ., Update of the drug resistance mutations in HIV-1: December 2010. Top. HIV Med. 18, 156\u2013163 (2010).","journal-title":"Top. HIV Med."},{"key":"e_1_3_4_6_2","doi-asserted-by":"publisher","DOI":"10.1021\/acs.molpharmaceut.7b01004"},{"key":"e_1_3_4_7_2","doi-asserted-by":"publisher","DOI":"10.1021\/bc300076f"},{"key":"e_1_3_4_8_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.95.26.15613"},{"key":"e_1_3_4_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.01339-10"},{"key":"e_1_3_4_10_2","doi-asserted-by":"publisher","DOI":"10.1186\/s12977-019-0489-7"},{"key":"e_1_3_4_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02279-09"},{"key":"e_1_3_4_12_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.1217443109"},{"key":"e_1_3_4_13_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.00644-12"},{"key":"e_1_3_4_14_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature12746"},{"key":"e_1_3_4_15_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2016.05.024"},{"key":"e_1_3_4_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.02108-09"},{"key":"e_1_3_4_17_2","volume-title":"Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers","author":"Food and Drug Administration","year":"2005","unstructured":"Food and Drug Administration, Guidance for Industry: Estimating the Maximum Safe Starting Dose in Initial Clinical Trials for Therapeutics in Adult Healthy Volunteers, (Department of Health and Human Services, Food and Drug Administration, Rockville, MD, 2005)."},{"key":"e_1_3_4_18_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.meegid.2015.09.006"},{"key":"e_1_3_4_19_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1909512"},{"key":"e_1_3_4_20_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1904398"},{"key":"e_1_3_4_21_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1711460"},{"key":"e_1_3_4_22_2","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3018(19)30238-3"},{"key":"e_1_3_4_23_2","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1016\/S2352-3018(19)30372-8","article-title":"Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: An open-label, phase 1b, consecutive-panel trial","volume":"7","author":"Sch\u00fcrmann D.","year":"2020","unstructured":"D. Sch\u00fcrmann ., Safety, pharmacokinetics, and antiretroviral activity of islatravir (ISL, MK-8591), a novel nucleoside reverse transcriptase translocation inhibitor, following single-dose administration to treatment-naive adults infected with HIV-1: An open-label, phase 1b, consecutive-panel trial. Lancet HIV 7, e164\u2013e172 (2020).","journal-title":"Lancet HIV"},{"key":"e_1_3_4_24_2","volume-title":"Guide for the Care and Use of Laboratory Animals","author":"National Research Council","year":"1985","unstructured":"National Research Council, Guide for the Care and Use of Laboratory Animals, (NIH Pub. No. 86-23, Department of Health and Human Services, Washington, DC, ed. 6, 1985).","edition":"6"},{"key":"e_1_3_4_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.74.15.6935-6945.2000"},{"key":"e_1_3_4_26_2","doi-asserted-by":"publisher","DOI":"10.1038\/nature21435"},{"key":"e_1_3_4_27_2","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20132494"},{"key":"e_1_3_4_28_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.212511599"},{"key":"e_1_3_4_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.76.5.2123-2130.2002"},{"key":"e_1_3_4_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.62.1.139-147.1988"},{"key":"e_1_3_4_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JVI.79.10.6089-6101.2005"},{"key":"e_1_3_4_32_2","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.0708109104"}],"updated-by":[{"DOI":"10.1073\/pnas.2018252117","type":"correction","label":"Correction","source":"publisher","updated":{"date-parts":[[2020,9,14]],"date-time":"2020-09-14T00:00:00Z","timestamp":1600041600000}}],"container-title":["Proceedings of the National Academy of Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/pnas.org\/doi\/pdf\/10.1073\/pnas.2009700117","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,13]],"date-time":"2022-04-13T06:19:23Z","timestamp":1649830763000},"score":1,"resource":{"primary":{"URL":"https:\/\/pnas.org\/doi\/full\/10.1073\/pnas.2009700117"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,8,20]]},"references-count":32,"journal-issue":{"issue":"36","published-print":{"date-parts":[[2020,9,8]]}},"alternative-id":["10.1073\/pnas.2009700117"],"URL":"https:\/\/doi.org\/10.1073\/pnas.2009700117","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2020.04.14.041764","asserted-by":"object"}]},"ISSN":["0027-8424","1091-6490"],"issn-type":[{"value":"0027-8424","type":"print"},{"value":"1091-6490","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,8,20]]},"assertion":[{"value":"2020-08-20","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}